Targeting c-Met and EGFR Pathways to Inhibit Lung Cancer
Author Information
Author(s): Laura P. Stabile, Mary E. Rothstein, Phouthone Keohavong, Diana Lenzner, Stephanie R. Land, Autumn L. Gaither-Davis, K. Jin Kim, Naftali Kaminski, Jill M. Siegfried
Primary Institution: University of Pittsburgh
Hypothesis
Can dual targeting of c-Met and EGFR pathways provide better inhibition of lung tumorigenesis than targeting each pathway individually?
Conclusion
Dual targeting of the c-Met and EGFR pathways significantly reduces tumor formation in a mouse model of lung cancer.
Supporting Evidence
- HGF and AREG levels were significantly higher in lung cancer cases compared to controls.
- Combination treatment with L2G7 and gefitinib resulted in fewer tumors than single-agent treatments.
- Patients with elevated HGF and AREG levels had a higher probability of lung cancer.
- Dual inhibition of c-Met and EGFR pathways showed additive anti-tumor effects in mice.
Takeaway
This study shows that using two different treatments together can help stop lung cancer better than using just one treatment.
Methodology
The study analyzed serum levels of ligands in lung cancer patients and tested the effects of inhibitors in a transgenic mouse model.
Limitations
The study primarily focuses on a specific mouse model and may not fully represent human lung cancer complexities.
Participant Demographics
43 lung cancer cases and 28 smoking controls, with a higher mean age in cases.
Statistical Information
P-Value
p<0.001
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website